CL2023003033A1 - Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica. - Google Patents

Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica.

Info

Publication number
CL2023003033A1
CL2023003033A1 CL2023003033A CL2023003033A CL2023003033A1 CL 2023003033 A1 CL2023003033 A1 CL 2023003033A1 CL 2023003033 A CL2023003033 A CL 2023003033A CL 2023003033 A CL2023003033 A CL 2023003033A CL 2023003033 A1 CL2023003033 A1 CL 2023003033A1
Authority
CL
Chile
Prior art keywords
compositions
methods
pediatric
myasthenia gravis
treatment
Prior art date
Application number
CL2023003033A
Other languages
English (en)
Spanish (es)
Inventor
Shawn Black
Sindhu Ramchandren
Yaowei Zhu
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CL2023003033A1 publication Critical patent/CL2023003033A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2023003033A 2021-04-12 2023-10-11 Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica. CL2023003033A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163173919P 2021-04-12 2021-04-12
US202163219155P 2021-07-07 2021-07-07
US202263266880P 2022-01-18 2022-01-18

Publications (1)

Publication Number Publication Date
CL2023003033A1 true CL2023003033A1 (es) 2024-03-08

Family

ID=83640966

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003033A CL2023003033A1 (es) 2021-04-12 2023-10-11 Composiciones y métodos para el tratamiento de la miastenia gravis pediátrica.

Country Status (13)

Country Link
US (1) US20240182598A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323002A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517087A (cg-RX-API-DMAC7.html)
KR (1) KR20230169207A (cg-RX-API-DMAC7.html)
AU (1) AU2022256389A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021046A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003033A1 (cg-RX-API-DMAC7.html)
IL (1) IL307445A (cg-RX-API-DMAC7.html)
JO (1) JOP20230247A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012032A (cg-RX-API-DMAC7.html)
PH (1) PH12023552841A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
MA51032A (fr) * 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) * 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
IL280280B2 (en) * 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) * 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法

Also Published As

Publication number Publication date
AU2022256389A9 (en) 2023-12-07
KR20230169207A (ko) 2023-12-15
JOP20230247A1 (ar) 2023-10-12
MX2023012032A (es) 2023-12-08
JP2024517087A (ja) 2024-04-19
EP4323002A4 (en) 2025-04-16
PH12023552841A1 (en) 2024-05-20
WO2022221239A1 (en) 2022-10-20
BR112023021046A2 (pt) 2023-12-19
US20240182598A1 (en) 2024-06-06
AU2022256389A1 (en) 2023-11-30
IL307445A (en) 2023-12-01
CA3216642A1 (en) 2022-10-20
EP4323002A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
CO2021016768A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CO2021016765A2 (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
PE20200733A1 (es) Inhibidores de kras g 12c y metodos para su uso
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CO2022000260A2 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus métodos de uso
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2023009681A (es) Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
MX2018010993A (es) Derivados de icariina e icaritina.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
CO2022000481A2 (es) Inhibidores de enzimas
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2023012032A (es) Composiciones y métodos para tratar la miastenia gravis pediátrica.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
CO2025016192A2 (es) Moléculas y métodos de uso de estas
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций